← All trials
NCT06378021
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Apr 30, 2025
- First posted
- Apr 22, 2024
- Last posted
- Apr 22, 2024
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Helwan UniversityLead sponsor
- Helwan UniversitySponsor investigator
- Istanbul UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.